Literature DB >> 27443287

Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide.

Scott R Goldsmith1, Michael Slade1, John F DiPersio1, Peter Westervelt1, Steven J Lawrence2, Geoffrey L Uy1, Camille N Abboud1, Ravi Vij1, Mark A Schroeder1, Todd A Fehniger1, Erik R Dubberke2, Kathryn Trinkaus3, Rizwan Romee4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27443287      PMCID： PMC5394884          DOI： 10.3324/haematol.2016.149880

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation.

Authors:  Per Ljungman; Lena Perez-Bercoff; Jerker Jonsson; Gayane Avetisyan; Elda Sparrelid; Johan Aschan; Lisbeth Barkholt; Kajsa Larsson; Jacek Winiarski; Zhibing Yun; Olle Ringdén
Journal:  Haematologica       Date:  2006-01       Impact factor: 9.941

2.  Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.

Authors:  Shivaprasad Manjappa; Pavan Kumar Bhamidipati; Keith E Stokerl-Goldstein; John F DiPersio; Geoffrey L Uy; Peter Westervelt; Jingxia Liu; Mark A Schroeder; Ravi Vij; Camille N Abboud; Todd A Fehniger; Amanda F Cashen; Iskra Pusic; Meagan Jacoby; Srinidhi J Meera; Rizwan Romee
Journal:  Biol Blood Marrow Transplant       Date:  2013-10-10       Impact factor: 5.742

3.  CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia.

Authors:  Margaret L Green; Wendy M Leisenring; Hu Xie; Roland B Walter; Marco Mielcarek; Brenda M Sandmaier; Stanley R Riddell; Michael Boeckh
Journal:  Blood       Date:  2013-06-06       Impact factor: 22.113

4.  Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients.

Authors:  Ahmet H Elmaagacli; Nina K Steckel; Michael Koldehoff; Yael Hegerfeldt; Rudolf Trenschel; Markus Ditschkowski; Sandra Christoph; Tanja Gromke; Lambros Kordelas; Hellmut D Ottinger; Rudolf S Ross; Peter A Horn; Susanne Schnittger; Dietrich W Beelen
Journal:  Blood       Date:  2011-05-03       Impact factor: 22.113

5.  T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.

Authors:  Asad Bashey; Xu Zhang; Connie A Sizemore; Karen Manion; Stacey Brown; H Kent Holland; Lawrence E Morris; Scott R Solomon
Journal:  J Clin Oncol       Date:  2013-02-19       Impact factor: 44.544

6.  Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.

Authors:  Katsuto Takenaka; Tetsuya Nishida; Yuki Asano-Mori; Kumi Oshima; Kazuteru Ohashi; Takehiko Mori; Heiwa Kanamori; Koichi Miyamura; Chiaki Kato; Naoki Kobayashi; Naoyuki Uchida; Hirohisa Nakamae; Tatsuo Ichinohe; Yasuo Morishima; Ritsuro Suzuki; Takuhiro Yamaguchi; Takahiro Fukuda
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-26       Impact factor: 5.742

7.  Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.

Authors:  Philippe Armand; Haesook T Kim; Brent R Logan; Zhiwei Wang; Edwin P Alyea; Matt E Kalaycio; Richard T Maziarz; Joseph H Antin; Robert J Soiffer; Daniel J Weisdorf; J Douglas Rizzo; Mary M Horowitz; Wael Saber
Journal:  Blood       Date:  2014-04-17       Impact factor: 22.113

8.  Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.

Authors:  Krzysztof Mrózek; Guido Marcucci; Deedra Nicolet; Kati S Maharry; Heiko Becker; Susan P Whitman; Klaus H Metzeler; Sebastian Schwind; Yue-Zhong Wu; Jessica Kohlschmidt; Mark J Pettenati; Nyla A Heerema; AnneMarie W Block; Shivanand R Patil; Maria R Baer; Jonathan E Kolitz; Joseph O Moore; Andrew J Carroll; Richard M Stone; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544

9.  Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis.

Authors:  Pierre Teira; Minoo Battiwalla; Muthalagu Ramanathan; A John Barrett; Kwang Woo Ahn; Min Chen; Jaime S Green; Ayman Saad; Joseph H Antin; Bipin N Savani; Hillard M Lazarus; Matthew Seftel; Wael Saber; David Marks; Mahmoud Aljurf; Maxim Norkin; John R Wingard; Caroline A Lindemans; Michael Boeckh; Marcie L Riches; Jeffery J Auletta
Journal:  Blood       Date:  2016-02-16       Impact factor: 22.113

10.  CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML.

Authors:  S Ito; P Pophali; Wu CO; E K Koklanaris; J Superata; G A Fahle; R Childs; M Battiwalla; A J Barrett
Journal:  Bone Marrow Transplant       Date:  2013-04-08       Impact factor: 5.483
View more
  15 in total

1.  Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.

Authors:  Robin K Avery; Fernanda P Silveira; Kaitlin Benedict; Angela A Cleveland; Carol A Kauffman; Mindy G Schuster; Erik R Dubberke; Shahid Husain; David L Paterson; Tom Chiller; Peter Pappas
Journal:  Transpl Infect Dis       Date:  2018-03-30       Impact factor: 2.228

2.  Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study.

Authors:  David Beauvais; Elodie Drumez; Didier Blaise; Régis Peffault de Latour; Edouard Forcade; Patrice Ceballos; Anne Uyttebroeck; Hélène Labussière; Stéphanie Nguyen; Jean-Henri Bourhis; Patrice Chevallier; Anne Thiebaut; Xavier Poiré; Sébastien Maury; Eric Deconinck; Thomas Cluzeau; Eolia Brissot; Anne Huynh; Marie-Thérèse Rubio; Alain Duhamel; Ibrahim Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2020-12-18       Impact factor: 5.483

3.  Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide.

Authors:  Benedetta Rambaldi; Haesook T Kim; Carol Reynolds; Sharmila Chamling Rai; Yohei Arihara; Tomohiro Kubo; Leutz Buon; Mahasweta Gooptu; John Koreth; Corey Cutler; Sarah Nikiforow; Vincent T Ho; Edwin P Alyea; Joseph H Antin; Catherine J Wu; Robert J Soiffer; Jerome Ritz; Rizwan Romee
Journal:  Blood Adv       Date:  2021-01-26

4.  Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

Authors:  Fumiaki Jinnouchi; Yasuo Mori; Goichi Yoshimoto; Takuji Yamauchi; Takuya Nunomura; Ayano Yurino; Masayasu Hayashi; Junichiro Yuda; Takahiro Shima; Jun Odawara; Shuichiro Takashima; Kenjiro Kamezaki; Koji Kato; Toshihiro Miyamoto; Koichi Akashi; Katsuto Takenaka
Journal:  Int J Hematol       Date:  2021-10-15       Impact factor: 2.490

Review 5.  Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year.

Authors:  Helen E Heslop; Edward A Stadtmauer; John E Levine; Karen K Ballen; Yi-Bin Chen; Amy E DeZern; Mary Eapen; Mehdi Hamadani; Betty K Hamilton; Parameswaran Hari; Richard J Jones; Brent R Logan; Leslie S Kean; Eric S Leifer; Frederick L Locke; Richard T Maziarz; Eneida R Nemecek; Marcelo Pasquini; Rachel Phelan; Marcie L Riches; Bronwen E Shaw; Mark C Walters; Amy Foley; Steven M Devine; Mary M Horowitz
Journal:  Transplant Cell Ther       Date:  2021-08-27

Review 6.  A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection.

Authors:  Don Jeffrey Diamond; Corinna La Rosa; Flavia Chiuppesi; Heidi Contreras; Sanjeet Dadwal; Felix Wussow; Supriya Bautista; Ryotaro Nakamura; John A Zaia
Journal:  Expert Rev Vaccines       Date:  2018-10-03       Impact factor: 5.217

7.  Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis.

Authors:  Scott R Goldsmith; Muhammad Bilal Abid; Jeffery J Auletta; Asad Bashey; Amer Beitinjaneh; Paul Castillo; Roy F Chemaly; Min Chen; Stefan Ciurea; Christopher E Dandoy; Miguel Ángel Díaz; Ephraim Fuchs; Siddhartha Ganguly; Christopher G Kanakry; Jennifer A Kanakry; Soyoung Kim; Krishna V Komanduri; Maxwell M Krem; Hillard M Lazarus; Hongtao Liu; Per Ljungman; Richard Masiarz; Carolyn Mulroney; Sunita Nathan; Taiga Nishihori; Kristin M Page; Miguel-Angel Perales; Randy Taplitz; Rizwan Romee; Marcie Riches
Journal:  Blood       Date:  2021-06-10       Impact factor: 25.476

Review 8.  Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients.

Authors:  Lauren Stern; Barbara Withers; Selmir Avdic; David Gottlieb; Allison Abendroth; Emily Blyth; Barry Slobedman
Journal:  Front Microbiol       Date:  2019-05-28       Impact factor: 5.640

9.  Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.

Authors:  Andrew Lin; Jessica Flynn; Lauren DeRespiris; Bradley Figgins; Meagan Griffin; Carmen Lau; Anthony Proli; Sean M Devlin; Christina Cho; Roni Tamari; Ann A Jakubowski; Esperanza B Papadopoulos; Sergio A Giralt; Miguel-Angel Perales; Susan K Seo; Brian Shaffer
Journal:  Transplant Cell Ther       Date:  2020-10-11

10.  Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide.

Authors:  Albert Esquirol; Maria Jesús Pascual; Mi Kwon; Ariadna Pérez; Rocio Parody; Christelle Ferra; Irene Garcia Cadenas; Beatriz Herruzo; Nieves Dorado; Rafael Hernani; Isabel Sanchez-Ortega; Anna Torrent; Jorge Sierra; Rodrigo Martino
Journal:  Bone Marrow Transplant       Date:  2021-05-31       Impact factor: 5.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.